To evaluate OCT as an oral drug, it was given intermittently (three times per week) to a group of six dogs for a period of 4 weeks. Subsequently, it was changed to a daily administration (0.05 mgukg) for a period of 2 weeks. Finally the dose was reduced to 0.025 mgukg. Daily OCT 0.05 mgukg suppressed serum PTH by 67%. Subsequently, 0.025 mgukg maintained serum PTH within the normal range without hypercalcaemia for 4 weeks. The time course of serum OCT concentrations following a single i.v. or oral OCT dose to uraemic dogs showed that oral OCT was rapidly absorbed and reached maximum plasma concentration and its disappearance from blood was similar to that of i.v. injection. Conclusions. In conclusion, our results suggest that OCT is a useful vitamin D 3 analogue, with a potentially larger therapeutic window than that of i.v. 1,25(OH) 2 D 3 and which is available for i.v.uoral, in the management of 2HPT.
Introduction
1,25-Dihydroxyvitamin D 3 (1,25(OH) 2 D 3 , calcitriol) regulates parathyroid hormone (PTH) secretion directly by suppressing PTH gene transcription [1] and indirectly by increasing serum calcium through increased intestinal calcium absorption and bone mineral mobilization [2] . In the past two decades, 1,25(OH) 2 D 3 has been used widely for the treatment of secondary hyperparathyroidism (2HPT) and renal osteodystrophy. In 1984, Slatopolsky et al. [3] showed that intermittent i.v. administration of 1,25(OH) 2 D 3 to haemodialysis patients resulted in supraphysiological concentrations of 1,25(OH) 2 D 3 in serum and in minimization of calcaemic activity of 1,25(OH) 2 D 3 which markedly suppressed serum PTH without hypercalcaemia [3] . However, despite this regimen, 1,25(OH) 2 D 3 has often induced hypercalcaemia. One of the low calcaemic analogues of vitamin D, 1,25-dihydroxy-22-oxavitamin D 3 (22-oxacalcitriol, OCT), was shown to suppress PTH synthesis and secretion [4] .
In this study, we compare the relative potency of a single i.v. OCT (i.v. OCT) and 1,25(OH) 2 D 3 (i.v. 1,25(OH) 2 D 3 ) on serum PTH and ionized calcium (ICa) in dogs with chronic renal failure (CRF). In addition, we examine the efficacy of intermittent i.v. OCT. Several investigators have demonstrated that intermittent oral administration of 1,25(OH) 2 D 3 is effective in suppressing PTH secretion in haemodialysis [5] [6] [7] and continuous ambulatory peritoneal dialysis (CAPD) patients [8] .
A second goal of this study is to evaluate the possibility of OCT as an oral drug to patients with CRF and 2HPT. In addition, we compare the serum concentration of OCT following its i.v. or oral administration. 
Materials and methods

Materials
Animals and diets
Adult female beagle dogs were purchased from CSK Research Park, Inc. A dog model of chronic renal failure was prepared by a 5u6 nephrectomy with a standard two-step operation [9] . After 6-12 months of renal insufficiency, these dogs were used for the following studies.
Single-dose i.v. administration study Eight uraemic dogs were divided into two groups (i.v. OCT and i.v. 1,25(OH) 2 D 3 ) each having a similar degree of reduced kidney function estimated by creatinine clearance (i.v. OCT, 13.1"3.2 mlumin; i.v. 1,25(OH) 2 D 3 , 13.1"3.1 mlumin; compared with normal dog (ns11), 22.8"1.0 mlumin). Two dogs of each group were fed 250 guday of a diet containing 0.6% calcium and 1.0% phosphorus (Funabashi-Farms Co., Ltd, Japan), and the other dogs were fed a diet containing 0.4% calcium and 1.8% phosphorus (Funabashi Farms Co., Ltd) to induce more severe hyperparathyroidism. Uraemic dogs received vehicle (0.01% Tween 20 in phosphate-buffered saline) and OCT (0.01, 0.05, 0.1, 0.5, 1.0, and 5.0 mgukg) or 1,25(OH) 2 D 3 (0.001, 0.005, 0.01, 0.05, 0.1, and 0.5 mgukg) intravenously and blood was collected to measure serum ICa and intact PTH before and 24 h after the injection of OCT or 1,25(OH) 2 D 3 . Serum ICa was measured by a 634qqupH Analyzer (Ciba.Corning). To estimate the PTH concentrations in the dogs [10] , Allegro 1 intact PTH kit (Nicols Institute Laboratory, USA) was used.
Intermittent i.v. administration study
Eight uraemic dogs were classified into two categories (mild 2HPT : PTH -200 pguml; moderate 2HPT : PTH )200 pguml). Normal PTH levels in beagle dogs were 30.5"3.3 pguml (ns35). The six dogs with mild 2HPT were divided into two groups and given OCT (0.1 mgukg) or 1,25(OH) 2 D 3 (0.01, 0.02, and 0.05 mgukg) intravenously three times a week for a period of 13 weeks. The two dogs with moderate 2HPT were given only OCT (0.1 and 0.05 mgukg) at the same intervals and period. All dogs were maintained on a diet containing 0.6% calcium and 1.0% phosphorus. Blood was drawn from the forearm vein just before injection (72 h after previous injection) every week, and measured ICa and serum PTH. In addition, serum phosphorus, creatinine, alkaline phosphatase (ALP), albumin, and blood urea nitrogen (BUN) were measured by auto-analyzer COBAS 1 FARAII (Roche).
Oral administration study (intermittent and daily)
OCT was administered orally, intermittently (three times a week) to six uraemic dogs and two age-matched normal dogs for a period of 4 weeks. Subsequently, it was changed to a daily administration (0.05 mgukg) for a period of 2 weeks. Finally, the dose was reduced to 0.025 mgukg and it was given for an additional period of 4 weeks. OCT was dissolved in medium chain triglyceride (Nisshin Oil Mills, Ltd, Japan) and incorporated into capsules. The uraemic and normal dogs were maintained on a standard chow containing 1.1% calcium and 1.0% phosphorus (Clea Japan Inc. 
Statistical analysis
Results are expressed as mean"SEM. Statistical significance was determined by the Dunnett's one-tailed t-test for variable followed by Bartlett test (Figures 1, 2 and 4) or paired t-test (Tables 1 and 2 ) using SAS program. Dose-dependency in single-dose study was considered by Jonckheere test.
Results
Single-dose i.v. administration 
Intermittent i.v. administration
The effects of intermittent administration of OCT and 1,25(OH) 2 D 3 are depicted in Figures 2 and 3 . These compounds were given intravenously three times a week for a period of 13 weeks. In the first 5 weeks, treatment with OCT of 0.1 mgukg in dogs with mild 2HPT, there was no significant change in ICa; however, serum PTH decreased by 83% (21.4"7.4 pguml) compared with the initial PTH level (126.1"12.7 pguml) and this effect was maintained following 6 weeks without hypercalcaemia. 1,25 (OH) 2 D 3 at 0.025 mgukg suppressed PTH by 77% (from 100.4"17.5 to 22.3"10.1 pguml) without a significant increase in ICa. However, when the dose was increased to 0.05 mgukg, the ICa increased from 5.69"0.11 to 6.49"0.04 mgudl.
In the case of intermittent injection of OCT to two dogs with moderate 2HPT (Figure 3 ), in the first 3 weeks of treatment with OCT 0.1 mgukg, serum PTH decreased from 253.8 and 404.4 to 72.9 and 9.0 pguml, respectively. Subsequently, because of a mild increase of ICa in both dogs, the dose of OCT was reduced to 0.05 mgukg after 6 weeks of treatment. As a result, ICa returned to baseline, however, PTH remained suppressed for the entire length of the treatment period. There were no significant differences in serum chemistries (phosphorus, creatinine, BUN, albumin, and ALP) between pre-and post-treatment except for a mild increase in serum phosphorus and albumin in the 1,25(OH) 2 D 3 -treated group (Table 1) .
Intermittent and daily oral administration of OCT
The effect of oral treatment of OCT on PTH suppression in uraemic dogs is shown in Figure 4 . During the first 4 weeks, intermittent treatment with 0.05 mgukg OCT did not show significant suppression in serum PTH, although PTH decreased from 127.4"19.7 to 75.3"15.9 pguml. Daily treatment with the same dose for an additional week significantly decreased PTH from 75.3"15.9 to 24.6"11.5 pguml (67% decrease). After 1 week, this treatment induced an increase in ICa (6.18"0.20 mgudl). When the daily dose was reduced to 0.025 mgukg, the suppressive effect on PTH was maintained without hypercalcaemia throughout the treatment. After withdrawal, serum PTH returned to baseline in 1 week. In normal dogs, none of the doses of OCT, or the daily or intermittent treatment produced changes in ICa or serum PTH. No significant differences between pre-and post-treatment on serum chemistries were observed (Table 2) .
Serum concentration of OCT following single i.v. or oral
The time course of serum OCT concentrations following a single i.v. or oral therapeutic dose of OCT to uraemic dogs is shown in Table 3 and Figure 5 . All data of uraemic dogs with mild 2HPT are expressed as mean"SEM of three dogs. Paired pre-and post-treatment are assessed by t-test. *Data are serum chemistries in age-matched normal dogs. Following oral administration of 0.5, 1.0, or 2.0 mgukg OCT, the absorption was very rapid, with maximal serum concentrations (C max ) of 471.7, 492.8, and 1712.4 pguml, which peaked (T max ) at 1.0, 2.0, and 0.5 h, respectively. After reaching a peak, OCT disappeared from sera as rapidly as that observed for i.v. administration. The bioavailability, which was evaluated from AUC oraluAUC i.v. in each dose, was 50.0, 48.9, or 64.0%, respectively.
Discussion
The present study demonstrates that i.v. and oral OCT administrations are effective for the treatment of 2HPT in CRF without hypercalcaemia. In the past two decades, 1,25(OH) 2 D 3 has been used for the treatment of 2HPT associated with CRF because of its suppressive effect on PTH synthesis and secretion [1, 11] . In 1984, Slatopolsky et al. [3] reported that supraphysiological concentrations of 1,25(OH) 2 D 3 in serum induced by the administration of intravenous 1,25(OH) 2 D 3 resulted in marked suppression of PTH level without hypercalcaemia in haemodialysis patients [3] . However, in spite of a careful 1,25(OH) 2 D 3 dosage, hypercalcaemia frequently precludes its usage in patients with 2HPT.
OCT is an analogue of 1,25(OH) 2 D 3 synthesized to weaken its calcaemic activity. Several biological activities of this analogue, including a PTH suppressive effect, have been investigated in great detail [4, 12, 13] . Brown and co-workers [4] have reported that OCT suppressed PTH secretion and PTH mRNA with a potency similar to 1,25(OH) 2 D 3 with less calcaemic activity, and they also have demonstrated that a single dose of OCT suppressed PTH without hypercalcaemia in vivo in uraemic dogs. Fukagawa et al. [14] have shown that OCT suppressed PTH mRNA in uraemic rats without hypercalcaemia. Naveh-Many and Silver [15] have also reported that OCT decreased PTH mRNA in vitro and in vivo in rats. Recently, Denda and co-workers [16] have reported that OCT prevented the decrease of the parathyroid gland vitamin D receptor contents in uraemic rats.
Our current single-dose studies demonstrate that OCT suppressed PTH at doses ranging from 0.05 to 5.0 mgukg without significant increases of ICa, whereas, any of the effective doses of 1,25(OH) 2 D 3 were hypercalcaemic. In intermittent i.v. administration studies, both 1,25(OH) 2 D 3 (0.025 mgukg) and OCT (0.1 mgukg) were able to suppress PTH by about 80-90% without hypercalcaemia. This result clearly shows that OCT is effective in suppressing PTH as well as 1,25(OH) 2 D 3 . In this intermittent experiment, the effective dose of 1,25(OH) 2 D 3 without induction of hypercalcaemia was only 0.025 mgukg. On the other hand, OCT treatment in dogs with moderate 2HPT demonstrated that OCT was effective at doses ranging from 0.05 to 0.1 mgukg without hypercalcaemia. These results suggest that OCT is a useful therapeutic agent with a large therapeutic window for the management of 2HPT.
To evaluate the potential use of oral OCT in the control of 2HPT in patients on CAPD or pre-dialysis patients, OCT was administered orally to uraemic dogs with 2HPT. Oral doses of OCT of 0.05 mgukg, the minimal effective dose of OCT in the intermittent i.v. study, did not produce significant PTH suppression in the first 4 weeks of intermittent treatment. However, when followed by daily oral doses of 0.05 mgukg, PTH decreased to the normal range. Subsequent daily 0.025 mgukg doses maintained the PTH level in the normal range without induction of hypercalcaemia. These findings suggest that oral OCT is as effective as intermittent i.v. to suppress PTH.
During i.v. administration, a less calcaemic effect of OCT when compared with 1,25(OH) 2 D 3 has been observed, to be explained in part, as a result of its unique pharmacokinetic properties. Lower affinity of OCT for vitamin D-binding protein results in a shorter half-life in the circulation with increased access to target tissues [17, 18] . We next compared the serum OCT concentrations after either oral or i.v. administration. Oral OCT is rapidly absorbed and reaches effective concentrations to suppress PTH. Its disappearance from blood is similar to that of i.v. administration. This pharmacokinetic property may contribute to the efficacy of oral OCT treatment on PTH suppression without induction of hypercalcaemia.
Tsukamoto et al. [7] have reported that intermittent oral treatment of 1,25(OH) 2 D 3 'oral calcitriol pulse therapy' was effective in suppressing PTH in haemodialysis patients [7] . The short-term study by Martin et al. [8] has shown that treatment of 2HPT in patients on CAPD can be managed by the intermittent oral treatment of 1,25(OH) 2 D 3 which provides therapeutic serum concentration of calcitriol without hypercalcaemia. In our current study, daily oral administration of OCT suppressed serum PTH effectively without affecting ICa. Considering the compliance of CAPD or pre-dialysis patients, i.v. treatment is not practical. In the past two decades, oral calcitriol or alfacalcidol have been used empirically for the treatment of renal osteodystrophy in patients with chronic renal failure. Many studies have demonstrated a beneficial effect of 1,25(OH) 2 D 3 on bone disease. Based on the genesis of hyperparathyroidism in renal insufficiency, 1,25(OH) 2 D 3 supplementation is undoubtedly essential. It has also become clear that phosphorus retention plays an important role in the development and persistence of 2HPT [19] . However, the use of calcium carbonate as a phosphate binder instead of aluminum salts has limited the use of 1,25(OH) 2 D 3 because of the development of hypercalcaemia. Considering the prophylactic or therapeutic treatment with vitamin D for pre-dialysis or CAPD patients, an ideal agent should have the following characteristics: (i) a PTH suppressive effect in the absence of induction of hypercalcaemia and hyperphosphataemia; (ii) a conventional oral regimen; and (iii) a preventive or therapeutic effect on parathyroid bone disease. A previous study by Malluche's group [20] has demonstrated that i.v. OCT prevented parathyroid bone disease without inducing adynamic bone disease in uraemic dogs. From the above-described mechanisms, OCT seems to be a promising and a useful agent not only for haemodialysis patients but also for predialysis and CAPD patients. Furthermore, the present study suggests the possibility that OCT may be used as a flexible agent, because it is available for both intermittent i.v. or daily oral treatment, in the management of 2HPT. All data of uraemic dogs are expressed as mean"SEM of six dogs. Paired pre-and post-treatment are assessed by t-test. 
